ANVS · Annovis Bio Inc
United States · RS rating 8 · As of 2026-10-14
| Price | 1.02 USD |
|---|---|
| 1-day change | -3.8% |
| RS rating (overall / 1M / 3M / 12M) | 8 / 25 / 7 / 18 |
| Stage | Basing |
| Composite / Minervini / CANSLIM score | 19 / 13 / 16 |
| Industry group (rank) | Medical-Biomed/Biotech (167) |
| EPS growth Q/Q | +36.5% |
| Sales growth Q/Q | – |
| Distance from 52-week high | +80.0% |
| Market cap (USD) | $62.5M |